| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Streptococcal Infections | 25 | 2022 | 248 | 5.260 |
Why?
|
| Streptococcus agalactiae | 27 | 2022 | 103 | 4.430 |
Why?
|
| Chagas Disease | 7 | 2023 | 309 | 2.520 |
Why?
|
| Infectious Disease Transmission, Vertical | 10 | 2023 | 255 | 2.470 |
Why?
|
| Streptococcal Vaccines | 12 | 2019 | 18 | 1.840 |
Why?
|
| Intraabdominal Infections | 8 | 2024 | 19 | 1.740 |
Why?
|
| Pregnancy Complications, Parasitic | 3 | 2021 | 27 | 1.720 |
Why?
|
| Trypanosoma cruzi | 5 | 2021 | 251 | 1.620 |
Why?
|
| Pregnancy Complications, Infectious | 17 | 2024 | 497 | 1.550 |
Why?
|
| Antibodies, Bacterial | 15 | 2019 | 406 | 1.450 |
Why?
|
| Infant, Newborn, Diseases | 6 | 2019 | 180 | 1.220 |
Why?
|
| Polysaccharides, Bacterial | 6 | 2016 | 68 | 1.030 |
Why?
|
| Carrier State | 4 | 2019 | 78 | 0.950 |
Why?
|
| Bacterial Capsules | 4 | 2019 | 41 | 0.860 |
Why?
|
| Vaccines, Conjugate | 9 | 2019 | 83 | 0.830 |
Why?
|
| Pregnancy | 24 | 2024 | 7568 | 0.800 |
Why?
|
| Lymphadenitis | 1 | 2022 | 26 | 0.770 |
Why?
|
| Eye Diseases | 1 | 2023 | 117 | 0.740 |
Why?
|
| Eye | 1 | 2023 | 236 | 0.740 |
Why?
|
| Streptococcus pyogenes | 1 | 2022 | 79 | 0.730 |
Why?
|
| Skin Diseases | 1 | 2022 | 137 | 0.700 |
Why?
|
| Vancomycin | 3 | 2013 | 222 | 0.650 |
Why?
|
| Infant, Newborn | 22 | 2021 | 8574 | 0.600 |
Why?
|
| Meningitis, Bacterial | 3 | 2021 | 98 | 0.570 |
Why?
|
| Infant | 17 | 2022 | 13198 | 0.570 |
Why?
|
| Humans | 66 | 2024 | 132373 | 0.520 |
Why?
|
| Female | 49 | 2024 | 70809 | 0.510 |
Why?
|
| Immunoglobulin G | 11 | 2019 | 803 | 0.490 |
Why?
|
| Vaccines | 1 | 2020 | 381 | 0.460 |
Why?
|
| Anti-Bacterial Agents | 8 | 2021 | 2557 | 0.450 |
Why?
|
| Simplexvirus | 1 | 2014 | 100 | 0.440 |
Why?
|
| Chorioamnionitis | 1 | 2014 | 45 | 0.440 |
Why?
|
| Herpes Simplex | 1 | 2014 | 56 | 0.440 |
Why?
|
| Haemophilus Infections | 1 | 2014 | 97 | 0.410 |
Why?
|
| Haemophilus influenzae | 1 | 2014 | 136 | 0.410 |
Why?
|
| Stillbirth | 1 | 2014 | 103 | 0.400 |
Why?
|
| Drug Monitoring | 1 | 2013 | 175 | 0.360 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 897 | 0.350 |
Why?
|
| Bacterial Infections | 2 | 2013 | 324 | 0.350 |
Why?
|
| Infant, Premature | 3 | 2014 | 847 | 0.350 |
Why?
|
| Physicians | 1 | 2018 | 635 | 0.350 |
Why?
|
| Bacteremia | 5 | 2016 | 428 | 0.350 |
Why?
|
| Bartonella | 1 | 2010 | 10 | 0.340 |
Why?
|
| Bartonella Infections | 1 | 2010 | 7 | 0.340 |
Why?
|
| Opportunistic Infections | 2 | 2018 | 80 | 0.330 |
Why?
|
| Retinitis | 1 | 2010 | 16 | 0.330 |
Why?
|
| Adult | 26 | 2024 | 31624 | 0.330 |
Why?
|
| United States | 12 | 2024 | 11631 | 0.320 |
Why?
|
| Orbital Diseases | 1 | 2010 | 72 | 0.320 |
Why?
|
| Mothers | 3 | 2021 | 374 | 0.320 |
Why?
|
| Serotyping | 4 | 2018 | 178 | 0.310 |
Why?
|
| Premature Birth | 1 | 2014 | 419 | 0.310 |
Why?
|
| Sinusitis | 1 | 2010 | 113 | 0.310 |
Why?
|
| Malaria | 1 | 2010 | 103 | 0.300 |
Why?
|
| Conjunctivitis, Bacterial | 1 | 2008 | 5 | 0.290 |
Why?
|
| Thyroglossal Cyst | 1 | 2008 | 5 | 0.290 |
Why?
|
| Meningococcal Infections | 1 | 2008 | 20 | 0.290 |
Why?
|
| Hospitals, Pediatric | 1 | 2013 | 781 | 0.280 |
Why?
|
| Tetanus Toxoid | 3 | 2006 | 50 | 0.280 |
Why?
|
| Child | 17 | 2024 | 25835 | 0.280 |
Why?
|
| Brain Diseases | 1 | 2010 | 307 | 0.270 |
Why?
|
| Abscess | 1 | 2008 | 140 | 0.260 |
Why?
|
| Enterobacteriaceae Infections | 2 | 2021 | 56 | 0.250 |
Why?
|
| Streptococcus | 1 | 2006 | 63 | 0.250 |
Why?
|
| Diagnostic Imaging | 5 | 2024 | 315 | 0.230 |
Why?
|
| Male | 23 | 2024 | 65072 | 0.230 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2006 | 128 | 0.230 |
Why?
|
| Familial Mediterranean Fever | 1 | 2004 | 4 | 0.230 |
Why?
|
| Neutrophils | 2 | 2004 | 359 | 0.230 |
Why?
|
| Diverticulitis | 1 | 2024 | 8 | 0.220 |
Why?
|
| Cholecystitis, Acute | 1 | 2024 | 17 | 0.220 |
Why?
|
| Abdominal Abscess | 1 | 2024 | 27 | 0.220 |
Why?
|
| Cholangitis | 1 | 2024 | 40 | 0.220 |
Why?
|
| Fever of Unknown Origin | 1 | 2004 | 45 | 0.220 |
Why?
|
| Blood Culture | 1 | 2024 | 36 | 0.220 |
Why?
|
| Infant, Premature, Diseases | 2 | 2004 | 252 | 0.220 |
Why?
|
| Vagus Nerve | 1 | 2004 | 46 | 0.220 |
Why?
|
| Texas | 4 | 2015 | 3629 | 0.210 |
Why?
|
| Young Adult | 8 | 2019 | 9949 | 0.210 |
Why?
|
| Adolescent | 13 | 2018 | 20560 | 0.210 |
Why?
|
| Electric Stimulation Therapy | 1 | 2004 | 84 | 0.210 |
Why?
|
| Salivary Gland Diseases | 1 | 2003 | 5 | 0.200 |
Why?
|
| Child, Preschool | 7 | 2022 | 14862 | 0.200 |
Why?
|
| Rhizobium | 1 | 2003 | 4 | 0.200 |
Why?
|
| Appendicitis | 1 | 2024 | 133 | 0.200 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2002 | 36 | 0.190 |
Why?
|
| Cellulitis | 1 | 2022 | 62 | 0.190 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2003 | 91 | 0.190 |
Why?
|
| Vaccination | 4 | 2019 | 1017 | 0.180 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 1163 | 0.180 |
Why?
|
| Surgical Wound Infection | 1 | 2004 | 271 | 0.180 |
Why?
|
| Cronobacter sakazakii | 1 | 2021 | 4 | 0.180 |
Why?
|
| Phagocytosis | 5 | 2012 | 192 | 0.180 |
Why?
|
| Milk, Human | 1 | 2004 | 310 | 0.180 |
Why?
|
| Catheterization, Central Venous | 1 | 2003 | 139 | 0.180 |
Why?
|
| Prevalence | 3 | 2018 | 2665 | 0.170 |
Why?
|
| Antibody Specificity | 4 | 2016 | 201 | 0.170 |
Why?
|
| India | 2 | 2018 | 240 | 0.170 |
Why?
|
| Rectum | 2 | 2018 | 114 | 0.170 |
Why?
|
| Infant Formula | 1 | 2021 | 100 | 0.170 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2002 | 217 | 0.170 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2013 | 830 | 0.160 |
Why?
|
| Risk Factors | 4 | 2022 | 10912 | 0.160 |
Why?
|
| Vagina | 2 | 2018 | 206 | 0.160 |
Why?
|
| Retrospective Studies | 8 | 2013 | 17371 | 0.160 |
Why?
|
| Syndrome | 1 | 2022 | 1171 | 0.160 |
Why?
|
| Vaginosis, Bacterial | 1 | 2019 | 19 | 0.160 |
Why?
|
| Public Health | 1 | 2021 | 282 | 0.150 |
Why?
|
| Obesity | 1 | 2011 | 2406 | 0.150 |
Why?
|
| Biopsy | 2 | 2014 | 1289 | 0.150 |
Why?
|
| Trichosporonosis | 1 | 2018 | 8 | 0.150 |
Why?
|
| Invasive Fungal Infections | 1 | 2018 | 19 | 0.140 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 179 | 0.140 |
Why?
|
| Infectious Disease Medicine | 1 | 2018 | 11 | 0.140 |
Why?
|
| HIV Infections | 1 | 2010 | 2063 | 0.140 |
Why?
|
| Staphylococcal Infections | 3 | 2010 | 569 | 0.130 |
Why?
|
| Treatment Outcome | 6 | 2021 | 13020 | 0.130 |
Why?
|
| Immunoglobulin M | 3 | 2007 | 216 | 0.130 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2013 | 382 | 0.130 |
Why?
|
| Molecular Typing | 1 | 2016 | 34 | 0.130 |
Why?
|
| Epilepsy | 1 | 2004 | 891 | 0.130 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 308 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 1 | 2019 | 1556 | 0.120 |
Why?
|
| Middle Aged | 6 | 2018 | 28895 | 0.120 |
Why?
|
| Mass Screening | 1 | 2021 | 831 | 0.120 |
Why?
|
| Genome, Bacterial | 1 | 2016 | 213 | 0.110 |
Why?
|
| Acyclovir | 1 | 2014 | 47 | 0.110 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 7112 | 0.110 |
Why?
|
| Umbilical Cord | 1 | 2014 | 59 | 0.110 |
Why?
|
| Whole Genome Sequencing | 1 | 2016 | 327 | 0.110 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2014 | 16 | 0.110 |
Why?
|
| Cordocentesis | 1 | 2013 | 10 | 0.110 |
Why?
|
| Immunoglobulin A | 2 | 2005 | 219 | 0.110 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2014 | 35 | 0.110 |
Why?
|
| Whooping Cough | 1 | 2014 | 61 | 0.100 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2013 | 35 | 0.100 |
Why?
|
| Antigens, Viral | 1 | 2014 | 439 | 0.100 |
Why?
|
| Blood Bactericidal Activity | 1 | 2012 | 17 | 0.100 |
Why?
|
| Opsonin Proteins | 1 | 2012 | 20 | 0.100 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 1443 | 0.090 |
Why?
|
| Hearing Disorders | 1 | 2012 | 29 | 0.090 |
Why?
|
| United Kingdom | 1 | 2012 | 234 | 0.090 |
Why?
|
| Gestational Age | 2 | 2014 | 1228 | 0.090 |
Why?
|
| Immunization | 3 | 2014 | 312 | 0.090 |
Why?
|
| Genotype | 1 | 2018 | 2706 | 0.090 |
Why?
|
| Device Removal | 2 | 2004 | 225 | 0.090 |
Why?
|
| Drug Utilization | 1 | 2013 | 165 | 0.090 |
Why?
|
| Acute Disease | 2 | 2024 | 1176 | 0.090 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 816 | 0.090 |
Why?
|
| Case-Control Studies | 4 | 2013 | 3422 | 0.090 |
Why?
|
| Age of Onset | 2 | 2010 | 626 | 0.090 |
Why?
|
| Pallor | 1 | 2010 | 2 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1723 | 0.090 |
Why?
|
| Half-Life | 1 | 2011 | 158 | 0.090 |
Why?
|
| Aged | 5 | 2016 | 21386 | 0.090 |
Why?
|
| Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 1 | 2010 | 2 | 0.080 |
Why?
|
| Coma | 1 | 2010 | 57 | 0.080 |
Why?
|
| Organophosphonates | 1 | 2010 | 21 | 0.080 |
Why?
|
| Oxazines | 1 | 2010 | 26 | 0.080 |
Why?
|
| Placenta | 1 | 2014 | 542 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2024 | 3710 | 0.080 |
Why?
|
| Vision Disorders | 1 | 2012 | 217 | 0.080 |
Why?
|
| Developing Countries | 1 | 2012 | 288 | 0.080 |
Why?
|
| Deoxycytidine | 1 | 2010 | 83 | 0.080 |
Why?
|
| Sex Distribution | 1 | 2010 | 324 | 0.080 |
Why?
|
| Antimalarials | 1 | 2010 | 45 | 0.080 |
Why?
|
| Doxycycline | 1 | 2010 | 121 | 0.080 |
Why?
|
| Chemoprevention | 1 | 2010 | 53 | 0.080 |
Why?
|
| Adenine | 1 | 2010 | 119 | 0.080 |
Why?
|
| Blood | 1 | 2010 | 107 | 0.080 |
Why?
|
| Rifampin | 1 | 2010 | 120 | 0.080 |
Why?
|
| Drug Combinations | 1 | 2010 | 279 | 0.080 |
Why?
|
| Brain | 1 | 2021 | 3200 | 0.080 |
Why?
|
| Logistic Models | 2 | 2012 | 1840 | 0.080 |
Why?
|
| Microscopy | 1 | 2010 | 125 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2014 | 822 | 0.080 |
Why?
|
| Travel | 1 | 2010 | 125 | 0.070 |
Why?
|
| Neisseria meningitidis | 1 | 2008 | 20 | 0.070 |
Why?
|
| Hematoma | 1 | 2009 | 92 | 0.070 |
Why?
|
| Cefotaxime | 1 | 2008 | 39 | 0.070 |
Why?
|
| Pediatrics | 1 | 2018 | 1215 | 0.070 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2010 | 229 | 0.070 |
Why?
|
| Genomics | 1 | 2016 | 1652 | 0.070 |
Why?
|
| Hospitalization | 2 | 2021 | 1895 | 0.070 |
Why?
|
| Overweight | 1 | 2011 | 384 | 0.070 |
Why?
|
| Aging | 2 | 2005 | 1261 | 0.070 |
Why?
|
| Craniocerebral Trauma | 1 | 2009 | 139 | 0.070 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 3983 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 1672 | 0.070 |
Why?
|
| Developmental Disabilities | 1 | 2012 | 749 | 0.070 |
Why?
|
| Anti-HIV Agents | 1 | 2010 | 352 | 0.070 |
Why?
|
| Antibody Affinity | 1 | 2006 | 41 | 0.060 |
Why?
|
| Body Weight | 1 | 2011 | 1006 | 0.060 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2006 | 108 | 0.060 |
Why?
|
| Gentamicins | 2 | 2004 | 87 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2005 | 3745 | 0.060 |
Why?
|
| Seizures | 1 | 2010 | 895 | 0.060 |
Why?
|
| Colchicine | 1 | 2004 | 38 | 0.060 |
Why?
|
| Length of Stay | 1 | 2010 | 1380 | 0.060 |
Why?
|
| Soft Tissue Infections | 1 | 2005 | 91 | 0.050 |
Why?
|
| Escherichia coli | 1 | 2009 | 995 | 0.050 |
Why?
|
| Nafcillin | 1 | 2003 | 13 | 0.050 |
Why?
|
| Ticarcillin | 1 | 2003 | 8 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2006 | 827 | 0.050 |
Why?
|
| Salivary Glands | 1 | 2003 | 34 | 0.050 |
Why?
|
| Pneumocystis | 1 | 2002 | 10 | 0.050 |
Why?
|
| Breast Feeding | 1 | 2004 | 240 | 0.050 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2002 | 45 | 0.050 |
Why?
|
| Lung | 1 | 2010 | 1556 | 0.050 |
Why?
|
| Penicillins | 1 | 2003 | 155 | 0.050 |
Why?
|
| Prednisone | 1 | 2002 | 252 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2004 | 304 | 0.050 |
Why?
|
| Time Factors | 1 | 2012 | 6457 | 0.050 |
Why?
|
| Double-Blind Method | 3 | 2014 | 1649 | 0.040 |
Why?
|
| Sepsis | 1 | 2004 | 518 | 0.040 |
Why?
|
| Hematologic Neoplasms | 1 | 2003 | 294 | 0.040 |
Why?
|
| Streptococcus pneumoniae | 1 | 2002 | 381 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2021 | 329 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2003 | 479 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 5405 | 0.040 |
Why?
|
| Voriconazole | 1 | 2018 | 34 | 0.040 |
Why?
|
| Lipopeptides | 1 | 2018 | 36 | 0.040 |
Why?
|
| Echinocandins | 1 | 2018 | 44 | 0.040 |
Why?
|
| Amphotericin B | 1 | 2018 | 91 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2006 | 1997 | 0.040 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2019 | 114 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 1964 | 0.030 |
Why?
|
| Serogroup | 1 | 2017 | 63 | 0.030 |
Why?
|
| Neutropenia | 1 | 2018 | 205 | 0.030 |
Why?
|
| Fetal Blood | 2 | 2007 | 174 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 3088 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2018 | 313 | 0.030 |
Why?
|
| Virulence | 1 | 2016 | 279 | 0.030 |
Why?
|
| Vaccines, Synthetic | 2 | 2009 | 322 | 0.030 |
Why?
|
| Species Specificity | 1 | 2016 | 544 | 0.030 |
Why?
|
| Recombination, Genetic | 1 | 2016 | 442 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2016 | 494 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2017 | 6540 | 0.030 |
Why?
|
| Foodborne Diseases | 1 | 2014 | 12 | 0.030 |
Why?
|
| Models, Economic | 1 | 2014 | 55 | 0.030 |
Why?
|
| Triatoma | 1 | 2014 | 30 | 0.030 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2014 | 124 | 0.030 |
Why?
|
| Phylogeny | 1 | 2016 | 767 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2014 | 128 | 0.030 |
Why?
|
| Insect Vectors | 1 | 2014 | 113 | 0.030 |
Why?
|
| Antibody Formation | 1 | 2014 | 274 | 0.030 |
Why?
|
| Hearing Tests | 1 | 2012 | 16 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 571 | 0.020 |
Why?
|
| Vision Screening | 1 | 2012 | 7 | 0.020 |
Why?
|
| Postpartum Period | 1 | 2014 | 231 | 0.020 |
Why?
|
| Disease Notification | 1 | 2012 | 9 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2012 | 94 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2012 | 202 | 0.020 |
Why?
|
| Bacteriological Techniques | 1 | 2012 | 89 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 557 | 0.020 |
Why?
|
| Child Development | 1 | 2014 | 289 | 0.020 |
Why?
|
| Bacterial Proteins | 2 | 2007 | 930 | 0.020 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2009 | 28 | 0.020 |
Why?
|
| Ampicillin | 1 | 2009 | 58 | 0.020 |
Why?
|
| Acetylation | 1 | 2009 | 192 | 0.020 |
Why?
|
| Drainage | 1 | 2009 | 265 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 2007 | 118 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2851 | 0.020 |
Why?
|
| Coagulase | 1 | 2004 | 23 | 0.010 |
Why?
|
| Diphtheria-Tetanus Vaccine | 1 | 2004 | 3 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 2004 | 54 | 0.010 |
Why?
|
| Staphylococcus | 1 | 2004 | 68 | 0.010 |
Why?
|
| Incidence | 1 | 2012 | 3362 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 2004 | 170 | 0.010 |
Why?
|
| Catheters, Indwelling | 1 | 2004 | 157 | 0.010 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2004 | 177 | 0.010 |
Why?
|
| Hypotension | 1 | 2004 | 183 | 0.010 |
Why?
|
| Hypoxia | 1 | 2004 | 261 | 0.010 |
Why?
|
| Serum Albumin | 1 | 2002 | 114 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2002 | 190 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 2169 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2004 | 5153 | 0.010 |
Why?
|
| Animals | 1 | 2014 | 34996 | 0.010 |
Why?
|